Antidepressants Not Effective for Some Types of Depression




Dying tree in field

Antidepressant medications have been the mainstay of treatment for depressive disorders for decades. But these drugs may not be as effective as once believed, according to a new analysis published in the Journal of the American Medical Association (JAMA). Researchers at the University of Pennsylvania conducted a meta-analysis of data from trials of antidepressants and concluded that the drugs are not effective in mild to moderate depression.

The investigators examined the results of six randomized, placebo-controlled trials published from 1980 to 2009: three involving imipramine, a tricyclic antidepressant (TCA), and three involving paroxetine, a selective serotonin reuptake inhibitor (SSRI). Each trial lasted at least six weeks. In total, the meta-analysis included 718 adult patients with a Hamilton Depression Rating Scale (HDRS) score ranging from 10 to 39 at baseline. (The HDRS is a clinical standard used to measure the severity of depressive symptoms; a score of less than 7 is considered normal, or symptom remission, and a score of greater than 20 generally denotes at least moderate depression.) Slightly more than half (434) of the total number of patients in the meta-analysis were administered an active drug during their respective clinical trial, with the remaining 284 patients receiving a placebo.

Overall, the authors concluded that as the severity of depression increased, the effect of the antidepressant treatment increased. The authors noted a clinically significant difference with antidepressant treatment compared to placebo only in patients with baseline HDRS scores above 25, which indicates very severe depression. Treatment effects of antidepressants were negligible or nonexistent in patients with HDRS scores between 19 and 22 (severe depression) and less than 18 (mild to moderate depression). The authors speculate that any benefit from antidepressant therapy in mild to moderate depression may be due to the placebo effect.

So what is a patient with depression to do? The longest-standing treatment options may not be effective, and taking the drugs places patients at risks of drug interactions and harmful side effects, including suicidality and type 2 diabetes. With safe medications unavailable, patients with mild to moderate depression may achieve the most benefit from psychotherapy as first-line treatment. Some studies have even reported that psychotherapy is as effective as drug therapy in moderate and severe depression, though many maintain that a combination of psychotherapy and medication is the most effective treatment plan for more severe cases.

Patients with chronic depression, older patients, and patients with lower intelligence achieve less success with psychotherapy than comparative groups in moderate to severe depression. Alternatively, patients with depression who are married or experienced unemployment or recent stressful life events achieve significant success with psychotherapy alone. Though findings from these randomized, controlled trials support the effectiveness of psychotherapy in some cases depression, a related trial finds that the effectiveness of psychotherapy is only realized in the controlled setting of a clinical trial, and not in a normal outpatient setting. Findings like these underscore the need for individualized therapies and treatment settings for patients with all severities of depression.

Patients are not advised to change their depression treatment as a result of the new meta-analysis. The analysis only evaluated two drugs, each in three settings. It is not clear whether the results of the study can be extended to other TCAs or SSRIs or other classes of antidepressants. More research is needed to identify the etiology and pathology of depression, as well as the subgroups related to depression severity. Treatment options should always be tailored to individual needs and outcomes.

Reference

Fournier, J., DeRubeis, R., Hollon, S., Dimidjian, S., Amsterdam, J., Shelton, R., & Fawcett, J. (2010). Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis JAMA: The Journal of the American Medical Association, 303 (1), 47-53 DOI: 10.1001/jama.2009.1943

Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, Gallop R. Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol. Aug 2009;77(4):775-787.

Gibbons CJ, Fournier JC, Stirman SW, Derubeis RJ, Crits-Christoph P, Beck AT. The clinical effectiveness of cognitive therapy for depression in an outpatient clinic. J Affect Disord. Jan 15.

Torpey, D., & Klein, D. (2009). Chronic depression: Update on classification and treatment Current Psychiatry Reports, 10 (6), 458-464 DOI: 10.1007/s11920-008-0074-6

  • http://addiction-dirkh.blogspot.com Dirk Hanson

    Finally, an objective and balanced account to counteract the recent flurry of “Anti-Depressants Don’t Work” stories. Thank you. The point of this study and the earlier controversial placebo study is: SSRI anti-depressants don’t work–for people who shouldn’t be taking them in the first place. They are medications for serious clinical depression. Always have been.

    • http://chipur.com Bill White

      Great comment, Dirk. Physicians are emptying their rx pads for folks looking for quick relief – or what worked for the guy or gal at work. I suppose it’s so much easier to buckle under a patients request than to stand for other/better treatment approaches.

  • http://chipur.com Bill White

    Well, I’m certainly not surprised by the study’s findings. As I was reading the antidepressants used in the work I was wondering about the other SSRIs and SSNRIs. Of course, that was addressed at the end of the piece. Interesting bit about the placebo effect. I’ve often wondered if that isn’t the real key to the efficacy of antidepressant therapy in mild depression and anxiety. But it’s a heck of a potential physical price to pay for the illusion of feeling better. Yet, some definitely “feel better.” And then you have to wonder if pharma knew all along that dynamic would bring waves of long-term sales their way. Hmmm. Always interesting stuff here. I like the new look, by the way.

  • wei

    there was a huge (near 3000 patients) pharmacogenetics study called Star*D to find genetic predictors for various antidepressants, where an enrollment criteria of hamd (17 items) >14 was used. I hope they can find some ways to reconcile with this publication.

  • Simon Dosovitz

    Good post, but the comment about SSRI and type 2 diabetes was thrown in there haphazardly. The DPP did show a connection, but an odd one in that the lifestyle group taking antidepressants showed a greater risk than than the placebo arm taking antidepressants, which is quite odd. Most importantly, the study was the DPP, which looked only at pre-diabetics or those who already had glucose control problems. No need to scare people with preliminary findings on a group of people they may or may not be included in.

Jennifer Gibson, PharmD

Jennifer Gibson, PharmD, is a practicing clinical pharmacist and medical writer/editor with experience in researching and preparing scientific publications, developing public relations materials, creating educational resources and presentations, and editing technical manuscripts. She is the owner of Excalibur Scientific, LLC.
See All Posts By The Author

Do not miss out ever again. Subscribe to get our newsletter delivered to your inbox a few times a month.